GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » hVIVO PLC (FRA:CRO) » Definitions » Capex-to-Revenue

hVIVO (FRA:CRO) Capex-to-Revenue : 0.17 (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is hVIVO Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

hVIVO's Capital Expenditure for the six months ended in Dec. 2023 was €-5.56 Mil. Its Revenue for the six months ended in Dec. 2023 was €33.37 Mil.

Hence, hVIVO's Capex-to-Revenue for the six months ended in Dec. 2023 was 0.17.


hVIVO Capex-to-Revenue Historical Data

The historical data trend for hVIVO's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

hVIVO Capex-to-Revenue Chart

hVIVO Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.05 0.02 0.03 0.09

hVIVO Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.05 0.01 0.01 0.17

Competitive Comparison of hVIVO's Capex-to-Revenue

For the Biotechnology subindustry, hVIVO's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


hVIVO's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, hVIVO's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where hVIVO's Capex-to-Revenue falls into.



hVIVO Capex-to-Revenue Calculation

hVIVO's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-6.009) / 65.052
=0.09

hVIVO's Capex-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-5.561) / 33.367
=0.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


hVIVO  (FRA:CRO) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


hVIVO Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of hVIVO's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


hVIVO (FRA:CRO) Business Description

Traded in Other Exchanges
Address
42, New Road, Queen Mary Bioenterprises Innovation Centre, London, GBR, E1 2AX
hVIVO PLC is a European-focused, rare, and orphan drug consulting services platform. The principal activity of the Group is that of a rapidly growing specialist CRO pharmaceutical services company, which involves the testing of vaccines and antivirals using human-challenge clinical trials. The group is also engaged in Venn Life Sciences' Clinical Research Division, providing a suite of consulting and clinical trial services to pharmaceutical, biotechnology, and medical device organizations.

hVIVO (FRA:CRO) Headlines

No Headlines